Your browser doesn't support javascript.
loading
Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors.
Xiao, Lu-Shan; Hu, Cheng-Yi; Cui, Hao; Li, Rui-Ning; Hong, Chang; Li, Qi-Mei; Huang, Chao-Yi; Dong, Zhong-Yi; Zhu, Hong-Bo; Liu, Li.
Affiliation
  • Xiao LS; Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Hu CY; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Cui H; Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Li RN; Department of Infectious Diseases, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
  • Hong C; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Li QM; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Huang CY; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Dong ZY; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Zhu HB; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Liu L; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Cancer Med ; 11(24): 4880-4888, 2022 12.
Article in En | MEDLINE | ID: mdl-35599583

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Liver Neoplasms / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2022 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Liver Neoplasms / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2022 Document type: Article Affiliation country: China